Angion Biomedica has initiated Phase II of multicentre trial to evaluate the safety of BB3 for the treatment of heart attack (acute myocardial infarction) in conjunction with standard-of-care and its efficacy in improving heart function in patients who have had their first heart attack.

The first patient of the double-blind, placebo-controlled study, which is expected to enrol 80 patients, was treated at Yale-New Haven Hospital, Connecticut, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is designed to randomise patients in 1:1 with either BB3 or placebo. Efficacy endpoints include myocardial infarct size, end diastolic volume, and left ventricular ejection fraction.

"This exciting study will provide key insights as to whether the encouraging data we generated in preclinical models will translate to patient benefit."

Yale New Haven Hospital principal investigator and Yale School of Medicine associate professor of medicine Frank Giordano said the hospital believed that BB3 was a promising therapy for the treatment of acute myocardial infarction.

"This trial will provide valuable data not only on the safety of BB3 in this population, but also whether this molecule can preserve heart muscle, promote beneficial healing of the heart, and improve clinical outcomes in patients suffering acute myocardial infarction," Giordano said.

See Also:

BB3 is a small molecule mimetic of hepatocyte growth factor (HGF), which has been formulated for intravenous infusion and oral administration, according to the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In preclinical studies, BB3 has demonstrated the ability to not only protect healthy cells surrounding the heart tissue from dying, but also the capactiy to promote tissue regeneration following a heart attack.

Angion Biomedica Itzhak Goldberg said: "This exciting study will provide key insights as to whether the encouraging data we generated in preclinical models will translate to patient benefit."